Lipoprotein (a) and other Lipid Profile in Patients with Thrombotic Stroke: Is it a Reliable Marker?

ABSTRACT

Background: Cerebrovascular disease (CVD) and coronary heart disease (CHD) cause 40%-50% of deaths in developed countries with CVD causing 10%-12% of deaths. Though increased Lipoprotein (a) is a risk factor in developing CHD, its role is poorly defined in etiopathogenesis of CVD.

Aims: To find the association of lipoprotein (a) and lipid profile in thrombotic stroke patients after acute phase.

Settings and Design: The study was conducted at Kasturba Medical College, Manipal. Twenty one cases of thrombotic stroke and 18 cases of age and sex matched controls were taken for the study. Informed consent was taken from both case and control.

Materials and Methods: Overnight fasting sample was collected from both case and control. Serum was separated and parameters such as total cholesterol, triglycerides, high density lipoproteins-C, low density lipoprotein-C, lipoprotein (a), fasting blood sugars were estimated. Statistical analysis: Data were analyzed by SPSS software, Student′s t-test, standard deviation (SD), and standard error of mean (SEM), P-value <0.05 is considered to be significant.

Results: In this study, we found no statistical significant differences in serum lipid and lipoprotein (a) profile between controls and thrombotic stroke patients.

Conclusions: Highest frequency (38%) of stroke was found in the age group of 7080 years. There were other associated risk factors such as diabetes in five cases (24%), hypertension in nine cases (43%), and family history of stroke in four cases. However, further studies are required to evaluate the importance of serum Lp(a) estimation in the assessment as a risk factor for thrombotic stroke.

Keywords

Lp(a) - lipid profile - thrombotic stroke

Publication History

Article published online:
29 January 2020

• REFERENCES

• 1 Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebro vascular disease in the community: Results of a WHO collaborative study. Bull World Health Organ 1980;58:113-30.
• 2 Smith WS, Hauser SL, Easton JD. Ischemic Stroke. In: Braunwald E, editor. Harrisons Principles of internal medicine. 15^th ed. New York: Mc Graw Hill Medical publishing division; 2001. p. 2369.
• 3 Fieschi C, Argentino C, Rasura M. Italian study of reversible ischemic attacks. Report of a meeting in Rome, Oct. 14-16, 1980. Stroke 1981;12:293-5.
• 4 Von Arbin M, Britton M, De Faire U, Tisell A. Circulatory Manifestations and Risk Factors in Patients with Acute Cerebrovascular Disease and in Matched Controls. Acta Med Scand 1985;218:373-80.
• 5 Pessah-Rasmussen H, Engstrom G, Jerntorp I, Janzon L. Increasing stroke incidence and decreasing case fatality, 1989- 1998: A study from the stroke register in Malmo, Sweden. Stroke 2003;34:913-8.
• 6 Community prevention and control of cardiovascular diseases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1986;732:1-62.
• 7 Lippi G, Guidi G. Lipoprotein (a): From ancestral benefit to modern pathogen? QJM 2000;93:75-84.
• 8 Trommsdorff M, Köchl S, Lingenhel A, Kronenberg F, Delport R, Vermaak H, et al. A pentanucleotide repeat polymorphism in the 5′ control region of the apolipoprotein (a) gene is associated with lipoprotein (a) plasma concentrations in Caucasians. J Clin Invest 1995;96:150-7.
• 9 Lippi G, Guidi G. Standardization and clinical management of lipoprotein (a) measurements. Clin Chem Lab Med 1998;36:5-16.
• 10 Mclean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, et al. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature 1987;330:132-7.
• 11 Milionis HJ, Winder AF, Mikhailidis DP. Lipoprotein (a) and stroke. J Clin Pathol 2000;53:487-96.
• 12 Utermann G, Hoppichler F, Dieplinger H, Seed M, Thompson G, Boerwinkle E. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: Multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc Natl Acad Sci U S A 1989;86:4171-4.
• 13 Rath M, Niendorf A, Reblin T, Dietel M, Krebber HJ, Belslegel U. Detection and quantification of lipoprotein (a) in the arterial wall of 107 coronary bypass patients. Arterioscler Thromb Vasc Biol 1989;9:579-92.
• 14 Aznar J, Estellés A, Bretó M, España F. Euglobin clot lysis induced by tissue type plasminogen activator in subjects with increased levels and different isoforms of lipoprotein (a). Thromb Res 1993;72:459-65.
• 15 Edelberg JM, Pizzo SV. The inhibition of tissue type plasminogen activator inhibitor- 1. The effects of Fibrinogen, Heparin, Vitronectin and lipoprotein (a). J Biol Chem 1991;266:7488- 93.
• 16 Buechler C, Ullrich H, Ritter M, Porsch-Oezcueruemez M, Lackner KJ, Barlage S, et al. Lipoprotein (a) up- regulates the expression of the plasminogen activator inhibitor 2 in human blood monocytes. Blood 2001;97:981-6.
• 17 Caplice NM, Panetta C, Peterson TE, Kleppe LS, Mueske CS, Kostner GM. Lipoprotein (a) binds and inactivates tissue factor pathway inhibitor: A novel link between lipoproteins and thrombosis. Blood 2001;98:2980-7.
• 18 Graigner DJ, Kirchenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein (a). Science 1993;260:1655-8.
• 19 Dalal P. Strokes (CVD) in India: Session 1- 9: The first Asian pacific symposium on Stroke: Sesson I, Panel discussion present status of stroke problems in each country. Jpn Circ J 1982;46:621-4.
• 20 Hachinski V, Graffagnino C, Beaudry M, Bernier G, Buck C, Donner A, et al. Lipids and stroke: A paradox resolved. Arch Neurol 1996;53:303-8.
• 21 Slunga L, Johnson O, Dahlen GH, Eriksson S. Lipoprotein (a) and acute- phase proteins in acute myocardial infarction. Scand J Clin Lab Invest 1992;52:95-101.
• 22 Ridker PM, Stampfer MJ, Hennekens CH. Plasma concentration of lipoprotein (a)and the risk of future stroke. JAMA 1995;273:1269-73.